Development and Commercialization Reports. Within 50 days of the Effective Date and at least 10 days before each anniversary of the Effective Date, TGTX shall provide to CTI a written report describing the efforts by TGTX, or any Affiliates or Sublicensees, to bring one or more Licensed Products to the marketplace. The report must be in sufficient detail to permit CTI to monitor TGTX’ compliance with the due diligence provisions of this Agreement. TGTX shall include at least the following in these reports: (a) a summary of TGTX’ progress toward meeting the goals and objectives that had been established for the previous year; (b) a summary of TGTX’ goals and objectives for the ensuing year for developing and commercializing Licensed Products, including an identification of Licensed Products that TGTX intends to develop, if any; and (c) to the extent not covered by the foregoing, a summary of TGTX’ progress in meeting the Milestone timelines above. If multiple technologies are covered by this Agreement, the progress report must provide the information set forth above for each Licensed Product.
Development and Commercialization Reports. During the Royalty Term for a Licensed Product in any of [***], subject to Section 5.7.3(a), AbbVie shall provide a summary [***] to Morphic of its Development and Commercialization activities with respect to such Licensed Products conducted since the last such summary was provided hereunder (or since the Effective Date with respect to the first such summary) and the Parties shall meet [***] at a mutually agreed time and place to discuss such summary; provided that, in the event Morphic merges or consolidates with, or otherwise acquires, or is acquired by, a Third Party (including through a Change of Control) and thereafter Morphic or any of its Affiliates (including any Pre-Existing Entity) Exploits a Competing Product, the foregoing obligation shall terminate as of the date of such merger, consolidation or acquisition. Prior to the start of the Royalty Term for a Licensed Product in any of [***], subject to Section 5.7.3(a), AbbVie shall provide a summary [***] to Morphic of its Development activities with respect to Licensed Products conducted since the last such summary was provided hereunder (or since the Effective Date with respect to the first such summary) and the Parties shall meet [***] at a mutually CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. agreed time and place to discuss such summary. Without limiting the foregoing, prior to the start of the Royalty Term for a Licensed Product in any of [***], upon Morphic’s request in any Calendar Quarter for which a summary is not provided in accordance with the immediately preceding sentence, the Parties shall meet and discuss AbbVie’s Development activities with respect to such Licensed Products, and AbbVie shall provide any Information with respect to such Development that is reasonably requested by Morphic.
Development and Commercialization Reports. Within 60 days of the Effective Date and on or before each anniversary of the Effective Date, CTI shall provide to DFCI a written report describing the efforts by CTI, or any Affiliates or Sublicensees, to bring one or more Licensed Products to the marketplace. The report must be in sufficient detail to permit DFCI to monitor CTI’ compliance with the due diligence provisions of this Agreement. CTI shall include at least the following in these reports: (a) a summary of CTI’s progress toward meeting the goals and objectives that had been established for the previous year; (b) a summary of CTI’s goals and objectives for the ensuing year for developing and commercializing Licensed Products, including an identification of Licensed Products that CTI intends to develop, if any; and (c) to the extent not covered by the foregoing, a summary of CTI’s progress in meeting the Milestone timelines above. If multiple technologies are covered by this Agreement, the progress report must provide the information set forth above for each Licensed Product.
Development and Commercialization Reports. ViroPharma shall keep INS reasonably informed of the progress of its efforts to Develop and Commercialize Products. Without limiting the foregoing, ViroPharma shall, *** the *** of *** a *** to *** and *** the ***.
Development and Commercialization Reports. At each JSC meeting or as otherwise agreed between the Parties, during the Term, GSK will provide the JSC with presentations regarding the Development activities performed by GSK, including without limitation [***]. GSK shall provide the JSC with a summary of [***] with respect to each GSK Development Compound. In addition, at the first meeting of the JSC following the exercise of the first GSK Program Option, GSK will provide the JSC with an initial outline of its [***], and thereafter will provide an update at each JSC meeting of Commercialization activities undertaken by GSK for that Product that have occurred since the last JSC meeting. Once a formal Global Commercialization Plan has been developed for each Product, in accordance with Section 4.2.1, GSK will provide the JSC updates on activities with respect to such Global Commercialization Plan at each JSC meeting.
Development and Commercialization Reports. On or before each anniversary of the Effective Date, Licensee shall provide to DFCI a written report describing the efforts by Licensee, or any Affiliates or Sublicensees, to research, develop and commercialize Developed Products and/or Licensed Products. The report must be in sufficient detail to permit DFCI to monitor Licensee’s compliance with the due diligence provisions of this Agreement. Licensee shall include at least the following in these reports: (a) a summary of Licensee’s progress toward meeting the goals and objectives that had been established for the previous year; (b) a summary of Licensee’s goals and objectives for the ensuing year for exploiting the Licensed Intellectual Property including an identification of additional Licensed Products that Licensee intends to develop, if any; and (c) to the extent not covered by the foregoing, a summary of Licensee’s progress in meeting the Diligence Benchmarks of Section 5.1.3.
Development and Commercialization Reports. NUPATHE shall keep complete and accurate records of its activities conducted under this Agreement and the results thereof. Following the conclusion of the Development Program and until the First Commercial Sale in the United States and the first Major European Country of the Product, within thirty (30) days after the end of each June and December, NUPATHE shall prepare and provide SMP with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date of such report to develop and obtain regulatory approvals to market the Product in major markets throughout the world. ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.
Development and Commercialization Reports. During the term of this Agreement, LICENSEE shall keep LICENSOR reasonably informed as to the progress of the development of PRODUCTS by notifying LICENSOR of completion of PHASE III studies for each such PRODUCT (to the extent such studies are commenced and completed). All information disclosed by LICENSEE pursuant to this Section 4.2 shall be treated as LICENSEE Confidential Information subject to Article 8 hereof. [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Development and Commercialization Reports. On or before each anniversary of the Effective Date, LICENSEE shall provide to DFCI a written report describing the efforts by LICENSEE, or any Affiliates or Sublicensees, to bring one or more Licensed Products to the therapeutic or diagnostic marketplace in Field of Use. In order to fulfill its obligation under this Section 5.1.2, LICENSEE shall be permitted to provide DFCI with a copy of letters or reports, and other information generally provided to shareholders of FibroGen. Notwithstanding the foregoing, such reports and letters must be in sufficient detail to permit DFCI to monitor LICENSEE’s compliance with due diligence provisions of this Agreement. At a minimum, LICENSEE shall include in these reports: (a) a summary of LICENSEE’s progress and (that of any Sublicensee) in the reporting year, related to exploiting the Licensed Intellectual Property including an identification of all Licensed Products that LICENSEE intends to develop, if any; and (b), a summary of all sublicenses that are currently in force and those that have been terminated, if any, in the reporting year.
Development and Commercialization Reports. Edge shall keep complete and accurate records of its activities conducted under this Agreement and the results thereof. Within thirty (30) days after the end of each calendar quarter until the First Commercial Sale of each Product on a country-by-country basis, Edge shall prepare and provide SurModics with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date of such report to develop and obtain regulatory approvals to market each Product in major markets throughout the world.
